Description
AptarGroup’s $65 Million Pharma Headwind: Could Q4 Mark a Major Turning Point?
AptarGroup, Inc.’s third-quarter 2026 results indicate a mixed performance with underlying growth offset by certain challenges. The company reported reported sales growth of 6% to just over $1 billion, with core sales up 5%, driven by all three segments—Pharma, Beauty, and Closures. However, gross margins declined 120 basis points year-over-year due primarily to lower sales of high-margin emergency medicine products and weaker margins in Beauty and Closures. Adjusted EBITDA decreased 2% to $217 million, with the consolidated margin narrowing to 21.3% from 23.2% the previous year. Adjusted earnings per share declined 6% to $1.52, impacted by lower EBITDA, higher interest expense, and a higher effective tax rate. Pharma sales showed a 1% core increase, or 8% excluding the expected emergency medicine destocking, which negatively affected growth and margins.



